Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management
作者: Katsutoshi OdaJunzo HamanishiKoji MatsuoKosei Hasegawa
作者单位: 1Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
2Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto, Japan
3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
4Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
5Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan
刊名: Gynecologic Oncology, 2018
来源数据库: Elsevier Journal
DOI: 10.1016/j.ygyno.2018.09.001
关键词: Ovarian clear cell carcinomaGenomicsNeoantigenImmune checkpointImmunotherapyOncogenesis
原始语种摘要: Abstract(#br)Ovarian clear cell carcinoma (OCCC) is distinctive from other histological types of epithelial ovarian cancer, with genetic/epigenetic alterations, a specific immune-related molecular profile, and epidemiologic associations with ethnicity and endometriosis. These findings allow for the exploration of unique and specific treatments for OCCC. Two major mutated genes in OCCC are PIK3CA and ARID1A , which are frequently coexistent with each other. Other genes' alterations also contribute to activation of the PI3K (e.g. PIK3R1 and PTEN ) and dysregulation of the chromatin remodeling complex (e.g. ARID1B , and SMARKA4 ). Although the number of focal copy number variations is small in OCCC, amplification is recurrently detected at chromosome 20q13.2 (including ZNF217 ), 8q, and 17q....
全文获取路径: Elsevier  (合作)
影响因子:3.929 (2012)

  • carcinoma 癌症
  • ovarian 卵巢的
  • clear 昧的
  • immunotherapy 免疫疗法
  • checkpoint 检查地点
  • management 管理